According to CNBC, if the US Food and Drug Administration approves the developers' application, the vaccine is likely to be applied in a limited and phased manner.
In this case, the first vaccinations will be given to medical workers, the elderly and people with concomitant diseases.
The next will be able to instill teachers, workers in shelters and prisons, and only then children and young people.
“Applying for permission to use a vaccine in an emergency in the United States is an important step towards making our candidate vaccine available to the world as soon as possible,” said Pfizer CEO Albert Burla.
The review process is expected to take several weeks, with a vaccine review advisory committee meeting scheduled for early December.
According to Pfizer, the approval will allow the vaccine to be used in high-risk groups in the United States by mid-to-end December 2020.
As previously reported, an analysis of data from clinical trials of the vaccine developed by Pfizer and BioNTech showed its effectiveness at the level of 95%.